KR101687774B1 - COMPOSITION COMPRISING EXTRACT OF Ainsliaea apiculata HAVING ANTI-OXIDANT AND ANTI-INFLAMMATORY ACTIVITY - Google Patents
COMPOSITION COMPRISING EXTRACT OF Ainsliaea apiculata HAVING ANTI-OXIDANT AND ANTI-INFLAMMATORY ACTIVITY Download PDFInfo
- Publication number
- KR101687774B1 KR101687774B1 KR1020150019387A KR20150019387A KR101687774B1 KR 101687774 B1 KR101687774 B1 KR 101687774B1 KR 1020150019387 A KR1020150019387 A KR 1020150019387A KR 20150019387 A KR20150019387 A KR 20150019387A KR 101687774 B1 KR101687774 B1 KR 101687774B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- inflammatory
- composition
- ainsliaea
- apiculata
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 58
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 24
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 14
- 241001038627 Ainsliaea apiculata Species 0.000 title claims description 15
- 235000006708 antioxidants Nutrition 0.000 title 1
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000013527 bean curd Nutrition 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 230000001629 suppression Effects 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 38
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 20
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 19
- 239000002158 endotoxin Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 229920006008 lipopolysaccharide Polymers 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 6
- 241000186216 Corynebacterium Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 5
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- -1 ABTS radicals Chemical class 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 3
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 3
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 3
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 2
- 101100190284 Arabidopsis thaliana PHE2 gene Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000186249 Corynebacterium sp. Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 229940119485 safflower extract Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZCUQOPGIJRGJDA-UHFFFAOYSA-N 1-naphthalen-1-ylethane-1,2-diamine Chemical compound C1=CC=C2C(C(N)CN)=CC=CC2=C1 ZCUQOPGIJRGJDA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012747 synergistic agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 항산화 및 항염증 활성을 가지는 좀딱취 추출물을 함유하는 항염증, 항산화 활성을 가진 조성물 및 식품조성물에 대한 것으로, 천연유래물질로 항산화 활성이 우수하고 염증인자 발현 억제 활성이 우수한 약학조성물과 식품조성물로 활용도가 우수하다.The present invention relates to a composition and a food composition having an anti-inflammatory and antioxidative activity and containing a mash extract having antioxidant and anti-inflammatory activity. The present invention relates to a pharmaceutical composition excellent in antioxidative activity and excellent in suppression of inflammatory factor expression, It is used for food composition.
Description
본 발명은 좀딱취(Ainsliaea apiculata) 추출물을 함유하는 항산화, 항염증활성의 약학조성물 및 식품조성물에 관한 것이다.The present invention relates to an antioxidant, antiinflammatory activity pharmaceutical composition and a food composition containing an extract of Ainsliaea apiculata .
항산화 기능은 체내에서 일어나는 산화반응을 억제시키거나 그 속도를 느리게 하는 것인데, 체내에서 일어나는 산화 반응은 노화의 유발과 세포의 변이를 유발하여 암세포를 생성한다. 따라서, 항산화 작용은 이런 체내의 부정적인 반응을 억제하기 위한 예방 방편으로 대중들도 관심이 많다.The antioxidant function inhibits or slows down the oxidation reaction occurring in the body. Oxidation reaction in the body induces aging and cell transformation to generate cancer cells. Therefore, the antioxidant activity is a preventive measure to suppress the negative reaction in the body, and the public is also interested.
한편, 체내에서는 세포 호흡과 더불어 에너지에 해당하는 ATP생성이 주기능인 세포 내의 미토콘드리아가 호흡의 부산물인 자유 라디칼(free radical)을 생성하고, 이는 불안정하여, 지질, 핵산, 단백질 등의 다른 물질과 급격하고 무차별적으로 반응한다. 따라서 이런 자유 라디칼의 생성을 막을 수 있다면 체내의 산화를 예방한다고 볼 수 있으며, 간접적으로는 노화와 암을 예방할 수 있어서 관심이 크다.On the other hand, in the body, mitochondria, which are main functions of ATP production, generate free radicals, which are byproducts of respiration, in addition to cell respiration, and they are unstable, And react indiscriminately. Therefore, if we can prevent the generation of these free radicals, we can prevent the oxidation of the body, and indirectly, we can prevent aging and cancer.
이런 항산화 효과는 인체 내에서 발생하는 자유 라디칼을 대상으로 실험하는 것에 무리가 있어 DPPH 및 ABTS 라디칼을 바이오마커로서 사용하고 있다. DPPH 자유라디칼 소거활성분석는 시료의 항산화능을 측정하는 방법 중의 하나로, 페놀성 화합물, 방향족 아민류 및 아스코르빈산 등에 의해 수소나 전자를 받아 환원되어 DPPH(1.1-diphenyl-2-picyl-hydrazyl)의 보라색이 탈색되는 원리를 이용하여 항산화 활성을 측정하는 방법으로 비교적 간단하고 짧은 시간 내에 항산화 활성을 측정할 수 있으며, 식물체의 항산화 활성과도 높은 연관성을 가지기 때문에 널리 사용되는 방법이다.These antioxidant effects are difficult to experiment with free radicals occurring in the human body and use DPPH and ABTS radicals as biomarkers. The DPPH free radical scavenging activity assay is one of the methods for measuring the antioxidant activity of a sample. The DPPH free radical scavenging activity assay is a method for measuring the antioxidative activity of DPPH (1,1-diphenyl-2-picyl-hydrazyl) This method of decolorizing antioxidant activity is a widely used method because it can measure antioxidative activity in a relatively short time and has a high correlation with the antioxidant activity of plants.
염증반응은 물리적 자극, 화학적 자극, 세균감염 등의 원인에 대한 생체의 방어기전 중 하나로, 외부 물질을 제거하고 손상부위를 수복 재생하려는 기전 중 하나이다. 염증 반응과 관련된 자극이 일단 가해지면, 국소적으로 히스타민(histamine), 세로토닌(serotonine), 브래디키닌(bradykinin), 프로스타그란딘(prostaglandin), HETE (hydroxyeicosatetraenoic acid), 류코트리엔(leukotriene)과 같은 혈관 활성 물질이 유리되어 혈관 투과성이 증대되면서 염증이 유발된다.Inflammation is one of the defenses of the body against physical stimuli, chemical stimuli, bacterial infections, etc. It is one of the mechanisms to remove external substances and regenerate damaged areas. Once an inflammation-related stimulus is applied, vasoactive substances such as histamine, serotonine, bradykinin, prostaglandin, hydroxyeicosatetraenoic acid (HETE), leukotriene And the vascular permeability is increased to cause inflammation.
단구세포는 세균감염 등으로 인해 활성화 되어 식세포작용을 하는 대식세포로 변화되며, 대식세포는 NO, 프로스타글란딘 E2, 전구염증성 사이토카인 등을 분비함으로써 염증을 유발하고, 염증, 면역반응 모두에서 중요한 조절세포로 작용하는데, 대식세포가 이렇게 작용하기 위해서는 반드시 활성화과정을 거쳐야 한다.Monocytes are transformed into macrophages that are activated by bacterial infection and act as phagocytic cells. Macrophages induce inflammation by secretion of NO, prostaglandin E2, and proinflammatory cytokines, and regulatory cells important in both inflammation and immune response In order for macrophages to function in this way, they must undergo an activation process.
그람 음성균의 세포벽 구성성분 중의 하나이며 내독소로 잘 알려진 LPS(lipopolysaccharide)는 대식 세포의 활성화에 관여하는 가장 잘 알려진 외부인자이다. 특히, RAW 264.7 세포와 같은 단구세포나 대식세포에서는 TNF-α(tumor necrosis factor-alpha), IL-6(interleukin-6), IL-1β(interleukin-1 beta)와 같은 전구염증성 사이토카인(pro-inflammatory cytokine)을 분비하여 염증부위에서 LPS(lipopolysaccharide)가 증가된다.LPS (lipopolysaccharide), one of the cell wall components of Gram-negative bacteria and well known as endotoxin, is the most well-known external factor involved in macrophage activation. Particularly, in monocytes and macrophages such as RAW 264.7 cells, proinflammatory cytokines such as TNF-α, IL-6 (interleukin-6) and IL-1β (interleukin- -inflammatory cytokine secreted by LPS (lipopolysaccharide) in the inflamed area.
LPS가 대식세포를 자극하게 되면 iNOS(inducible nitric oxide synthase)라는 효소에 의해 L-아르지닌(L-arginine)이 L-시트룰린(L-citrulline)으로 변하는 과정에서 NO(nitric oxide)가 생성됨으로써 대식세포는 NO를 생성한다.When LPS stimulates macrophages, nitric oxide (NO) is produced in the process of converting L-arginine into L-citrulline by an enzyme called iNOS (inducible nitric oxide synthase) Phagocytes produce NO.
포유동물에서 NO는 세 가지 종류의 NO 합성효소(NOS, nitric oxide synthease), 즉 nNOS(neuronal NOS), eNOS(endothelial NOS) 및 iNOS(inducible NOS)에 의해 합성된다. 이 중에서 nNOS와 eNOS에 의해 생성되는 NO는, 정상적인 생체기능을 위해 생성되며, 조직 내에서의 농도는 일정수준으로 낮게 유지된다. 그러나, iNOS에 의해 생성된 NO는 그 양이 과도하여 병리적인 혈관확장, 세포독성, 조직 손상 등과 같은 생체에 유해한 작용을 나타낸다. 또한, 염증인자인 프로스타글란딘 E2(PGE2)는 세포막의 구성성분인 인지질이 LPS에 의해 자극을 받아 포스포리파제 A2(phospholipase A2)라는 효소에 의해 유리된 아라키돈산이 COXs(cyclooxygenase)라고 불리는 효소의 촉매작용을 받아 형성되어 염증반응을 유도하게 된다. In mammals, NO is synthesized by three kinds of NO synthase (NOS): nNOS (neuronal NOS), eNOS (endothelial NOS) and iNOS (inducible NOS). Among these, NO produced by nNOS and eNOS is produced for normal biological function, and the concentration in tissues is kept low to a certain level. However, the amount of NO produced by iNOS is excessively high, and it is harmful to living organisms such as pathological vasodilation, cytotoxicity and tissue damage. In addition, prostaglandin E2 (PGE2), an inflammatory factor, stimulates phospholipid, which is a constituent of cell membrane, stimulated by LPS, and arachidonic acid liberated by an enzyme called phospholipase A2 causes catalytic action of an enzyme called COXs (cyclooxygenase) And is induced to induce an inflammatory reaction.
COX는 COX-1과 COX-2로 분류되는데, COX-1은 체내에서 혈소판의 형성, 위벽보호, 신장 기능의 유지 등 정상적인 생체기능에 작용하며 COX-2는 염증성 매개물질인 PHE2를 합성한다. PHE2는 염증반응(통증, 발열 등), 면역반응, 그리고 angiogenesis를 촉진하는 등 암 발생에도 깊이 관여하고 있는 것으로 알려져 있다. iNOS의 억제 약물은 그 작용기전이 COXs의 억제 물질과 연계되어 있어 경우가 대부분이다. 따라서 비교적 검색이 용이한 iNOS의 억제소재를 발굴하여 항염증 소재로 개발하는 경우가 많다.COX is classified as COX-1 and COX-2. COX-1 acts on normal biological functions such as platelet formation, gastric wall protection and maintenance of renal function in the body. COX-2 synthesizes PHE2 as an inflammatory mediator. PHE2 is known to be deeply involved in the development of cancer, such as promoting inflammation (pain, fever, etc.), immune response, and angiogenesis. Inhibition of iNOS is mostly due to its mechanism of action being linked to inhibitors of COXs. Therefore, iNOS inhibition materials that are relatively easy to search are discovered and developed as anti-inflammatory materials.
한편, 선택성 COX-2억제제(selective COX-2 inhibitors)를 포함하는 비스테로이드성 항 염증제(non-steroidal anti-inflammatory drugs, NSAIDs)는 항염증, 해열 및 진통 효과를 나타낸다. 하지만, 이러한 약들의 장기간 복용은 때로 심각한 부작용을 초래할 수 있다. 예를 들어, 위장관계의 소화성 궤양출혈로 인한 이차적 빈혈 초래, 혈소판 기능 억제, 분만 유도 억제, 신장에 대한 부작용, 간장 손상, 과민 반응 등이 있다.On the other hand, non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, have anti-inflammatory, antipyretic and analgesic effects. However, the long-term use of these drugs can sometimes lead to serious side effects. For example, secondary anemia due to gastrointestinal peptic ulcer bleeding, platelet function suppression, inhibition of induction of labor, side effects to the kidney, liver damage, hypersensitivity.
이러한 약물의 부작용을 극복하기 위하여 보다 안전한 소재로 식물과 같은 천연에서 유래한 제품은 선호도가 높으며, 이와 관련하여 천연물에서 그 항염증 소재를 찾아 활용하려는 연구들이 활발히 진행되고 있다.In order to overcome the side effects of these drugs, natural products such as plants are more preferable as a safer material. In this regard, researches are being actively carried out to find and use the anti-inflammatory materials in natural products.
좀딱취(Ainsliaea apiculata)는 쌍떡잎식물 초롱꽃목 국화과의 여러해살이풀로, 한국, 일본에서 서식하는 식물로(남도의 자생식물, 2005, 전라남도), 이 식물에 대한 항염증, 항산화 효과에 대한 연구는 보고된 바 없다. Ainsliaea apiculata is a perennial herbaceous perennial plant belonging to the family Asteraceae. It is a plant that lives in Korea and Japan (native plant of South Korea, 2005, Jeollanamdo), and its anti-inflammatory and antioxidant effects Not reported.
본 발명의 목적은 우수한 항산화 활성과 동시에 항염증 활성을 가지는 식물추출물을 함유하는 조성물을 제공하기 위한 것으로, 좀딱취(Ainsliaea apiculata)으로부터 추출한 성분이 자유라디칼 제거 활성이 우수하고 염증인자 발현 억제 활성도 갖는다는 점을 확인하여 이를 함유하는 약학적 조성물과 식품 조성물을 제공하는 것이다.An object of the present invention is to provide a composition containing a plant extract having excellent antioxidative activity and anti-inflammatory activity at the same time. The composition extracted from Ainsliaea apiculata has excellent free radical scavenging activity and inhibitory effect on inflammatory factor expression And to provide a pharmaceutical composition and a food composition containing the same.
본 발명의 일 실시예에 따른 항산화 조성물은 좀딱취(Ainsliaea apiculata) 추출물을 함유한다.The antioxidative composition according to one embodiment of the present invention contains Ainsliaea apiculata extract.
상기 좀딱취 추출물은 탄소수 1 내지 5의 알코올, 헥산, 클로로포름, 주정, 물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나로 냉침법을 이용해 추출한 것일 수 있다.The Corynebacterium extract may be one selected from the group consisting of alcohol having 1 to 5 carbon atoms, hexane, chloroform, alcohol, water, and a mixture thereof, and may be extracted by cold precipitation.
상기 좀딱취 추출물은 좀딱취의 건조분말에 건조중량의 3 내지 20배 부피의 중량의 용매를 가하고 20 내지 120 ℃의 추출 온도에서 30분 내지 10일 동안 추출하는 방법으로 1 내지 5회 추출하여 얻어진 추출액 또는 상기 추출액으로부터 용매를 제거한 분말 형태의 것일 수 있다.The extract of Corynebacterium sativus is obtained by extracting 1 to 5 times by adding a solvent having a dry weight of 3 to 20 times the weight of the dried powder to a dried bean curd and extracting it at an extraction temperature of 20 to 120 ° C for 30 minutes to 10 days An extract or a powder in which the solvent is removed from the extract.
상기 항산화 조성물은 DPPH 자유라디칼을 소거하는 것으로 확인된 항산화 활성을 가진 좀딱취 추출물을 함유하여 항산화 활성을 가지는 약학적 또는 식품 조성물로 유용하다.The antioxidant composition is useful as a pharmaceutical or food composition having an antioxidant activity by containing a scent extract having antioxidative activity, which is confirmed to scavenge DPPH free radicals.
상기 목적을 달성하기 위하여, 본 발명의 다른 일 실시예에 따른 항염증 조성물은 좀딱취(Ainsliaea apiculata)추출물을 함유한다.In order to achieve the above object, the anti-inflammatory composition according to another embodiment of the present invention contains Ainsliaea apiculata extract.
상기 좀딱취 추출물은 탄소수 1 내지 5의 알코올, 헥산, 클로로포름, 주정, 물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나로 냉침법을 이용해 추출한 것일 수 있다.The Corynebacterium extract may be one selected from the group consisting of alcohol having 1 to 5 carbon atoms, hexane, chloroform, alcohol, water, and a mixture thereof, and may be extracted by cold precipitation.
상기 좀딱취 추출물은 좀딱취의 건조분말에 건조중량의 3 내지 20배 중량의 용매를 가하고 20 내지 120 ℃의 추출 온도에서 30분 내지 10일 동안 추출하는 방법으로 1 내지 5회 추출하여 얻어진 추출액 또는 상기 추출액으로부터 용매를 제거한 분말일 수 있다.The extract is obtained by extracting 1 to 5 times by adding a solvent having a dry weight of 3 to 20 times by weight to a dry powder of bean curd and extracting it at an extraction temperature of 20 to 120 ° C for 30 minutes to 10 days, And may be a powder from which the solvent has been removed from the extract.
상기 항염증 조성물은 RAW 264.7 세포에서 LPS로 유도된 NO의 생성을 저해하는 것을 확인된 항염 활성을 가진 좀딱취 추출물을 함유하여 염증성 질환의 예방 또는 치료에 유용하다.The antiinflammatory composition is useful for the prevention or treatment of inflammatory diseases by containing a mash extract having anti-inflammatory activity which is confirmed to inhibit the production of NO induced by LPS in RAW 264.7 cells.
본 발명의 다른 일 실시예에 따른 식품조성물은, 좀딱취(Ainsliaea apiculata) 추출물을 함유한다. 상기 식품조성물은 항염증 활성과 항산화 활성을 가지며, 건강기능식품, 영양보조제, 건강식품, 또는 식품첨가물의 형태로 식품조성물로 활용될 수 있다.A food composition according to another embodiment of the present invention contains Ainsliaea apiculata extract. The food composition has anti-inflammatory activity and antioxidative activity and can be used as a food composition in the form of a health functional food, a nutritional supplement, a health food, or a food additive.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 실시예에 따른 항산화 약학조성물은 좀딱취(Ainsliaea apiculata) 추출물을 함유한다.The antioxidant pharmaceutical composition according to one embodiment of the present invention contains Ainsliaea apiculata extract.
상기 좀딱취 추출물은 좀딱취를 채취하여 건조 및 파쇄하여 분말화한 것을 용매를 이용하여 추출한 것일 수 있다. 상기 건조 및 파쇄되는 좀딱취는 좀딱취의 잎, 줄기, 뿌리, 꽃, 열매, 이들의 혼합, 또는 전초일 수 있으며, 건조는 채취한 좀딱취의 유용한 성분들이 파괴되지 않는 범위에서 공지의 방법으로 진행될 수 있고, 예를 들어 음지에서 자연건조의 방법으로 진행될 수 있다. 또한, 상기 파쇄는 이후 추출과정에서 좀딱취의 유용한 성분들이 충분하게 추출될 수 있을 정도로 파쇄하면 족하며 분말화하는 것이 바람직하다. 상기 건조와 파쇄 공정은 필요에 따라서 순서를 뒤바꿔서 진행하거나 반복하여 실시할 수 있다.The scarlet extract may be obtained by extracting scarlet, drying and crushing and pulverizing it with a solvent. The dried and crushed scarlet may be a scarlet leaf, stem, root, flower, fruit, mixture or outpost thereof. Drying may be carried out in a known manner to such an extent that useful components of the scarlet picked up are not destroyed And can proceed, for example, by a method of natural drying in the shade. In addition, it is preferable that the crushing is performed after crushing to such an extent that the useful components of the crushed stalks can be sufficiently extracted in the subsequent extraction process, and pulverized. The drying and crushing steps may be carried out in reverse order or repeatedly as required.
상기 추출은, 예를 들어, 열수 추출, 냉침 추출, 가온 추출, 환류 냉각 추출, 초음파 추출 등의 추출법이 적용될 수 있고, 바람직하게 냉침 추출법이 적용될 수 있다.The extraction may be carried out by, for example, hot water extraction, cold extraction, warming extraction, reflux cooling extraction, ultrasonic extraction, or the like, preferably by a cold extraction method.
상기 추출은 용매를 이용하여 진행되며, 상기 용매는 탄소수 1 내지 5의 알코올, 헥산, 클로로포름, 주정, 물 및 이들의 혼합물일 수 있고, 좋게는 물, 메탄올, 에탄올, 주정 및 이들의 혼합물을 포함하는 것일 수 있다.The extraction is carried out using a solvent, which may be an alcohol of 1 to 5 carbon atoms, hexane, chloroform, alcohol, water and mixtures thereof, preferably water, methanol, ethanol, .
상기 추출은 상기 좀딱취 건조 중량의 3 내지 20배, 바람직하게는 3 내지 10배에 달하는 중량의 용매를 이용하여, 20 내지 100 ℃, 좋게는 20 내지 70 ℃의 추출 온도에서 30분 내지 10일, 또는 1시간 내지 2일의 추출 시간 동안 추출하는 방법인, 좀딱취 추출물의 제조방법에 의하여 제조하여 상기 약학조성물의 제조에 적용할 수 있으며, 상기 좀딱취의 건조 및 파쇄물을 포함하여 1회 내지 5회, 바람직하게 2회 내지 3회 연속하여 추출하여 액상의 추출물을 수득할 수 있다.The extraction is carried out at a temperature of from 20 to 100 ° C, preferably from 20 to 70 ° C, for 30 minutes to 10 days, preferably from 3 to 20 times, preferably from 3 to 10 times, , Or a method of extracting for 1 to 2 days of extraction time. The method of the present invention can be applied to the production of the pharmaceutical composition, 5 times, preferably 2 times to 3 times, to obtain a liquid-phase extract.
상기 액상의 좀딱취 추출물은 감압여과 등의 방법으로 좀딱취 파쇄물과 분리된 후 농축 또는 건조의 과정을 거칠 수 있다. 예를 들어, 상기 액상의 좀딱취 추출물을 진공회전농축기로 20 내지 100 ℃, 바람직하게는 40 내지 70℃에서 감압 농축한 농축액일 수 있고, 상기 액상의 좀딱취 추출물을 건조하여 분말화된 좀딱취 추출물을 얻을 수도 있다. 이렇게 농축 또는 분말화된 좀딱취 추출물은 필요에 따라 물, 알코올 또는 이들의 혼합용매에 가용하여 사용될 수 있다. 또한, 상기 액상의 좀딱취 추출물, 이의 농축액 또는 이의 분말은 핵산 또는 에틸아세테이트에 의하여 분획 또는 상기 분획의 부분획을 하는 방법으로 추출된 추출물일 수 있다.The liquid morsel extract may be separated from a slightly scratched material by a method such as vacuum filtration, and then subjected to a concentration or drying process. For example, the liquid morsel extract may be concentrated in a vacuum rotary condenser at 20 to 100 ° C, preferably at 40 to 70 ° C, and the liquid morsel extract may be dried to obtain a powdered marshmallow Extracts may also be obtained. The concentrated or powdered morsel extract can be used as needed in water, alcohol or a mixed solvent thereof. In addition, the liquid morsel extract, the concentrate or the powder thereof may be an extract obtained by fractionation by nucleic acid or ethyl acetate or fractional stroke of the fraction.
체내에서는 세포 호흡과 더불어 에너지에 해당하는 ATP생성이 주기능인 세포 내의 미토콘드리아가 호흡의 부산물인 자유 라디칼(free radical)을 생성하고, 이는 불안정하여, 지질, 핵산, 단백질 등의 다른 물질과 급격하고 무차별적으로 반응한다. 이렇게, 체내에서 일어나는 산화 반응은 노화의 유발과 세포의 변이를 유발하여 이를 예방하거나 억제하기 위한 방편이 필요하다. 즉, 이런 자유 라디칼의 생성을 막을 수 있다면 체내의 산화를 예방한다고 볼 수 있으며, 간접적으로는 노화와 암을 예방할 수 있다. 본 발명은 강한 항산화 활성을 가지는 좀딱취 추출물을 포함하는 약학 조성물, 항암 보조제, 항산화제와 같은 건강기능식품 등으로 활용도가 높다.상기 항산화 조성물은 추가의 성분들을 더 포함할 수 있고, 예를 들어 담체, 부형제, 및 희석제 중에서 적어도 하나를 더 포함할 수 있으며, 예를 들어, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸셀룰로즈, 미정질셀룰로즈, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 및 광물유 중에서 적어도 하나 이상을 포함할 수 있다.In the body, mitochondria within the cell, which is the main function of ATP production, generate free radicals, a byproduct of respiration, which is unstable, and is accompanied by other substances such as lipids, nucleic acids and proteins, It reacts to the enemy. In this way, the oxidation reaction that occurs in the body induces aging and cell mutation, and it is necessary to prevent or suppress it. In other words, if we can prevent the generation of these free radicals, we can prevent the oxidation of the body and indirectly prevent aging and cancer. The antioxidant composition of the present invention may further include additional components. For example, the antioxidant composition may further include additional components such as antioxidants, antioxidants, The pharmaceutical composition may further comprise at least one of a carrier, an excipient and a diluent such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium May contain at least one or more selected from the group consisting of phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, have.
상기 항산화 조성물은, 다양한 제형을 가질 수 있는데, 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 외용제, 좌제 멸균 주사용액의 형태로 제형화 하여 사용될 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있으며, 비 경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The antioxidant composition may have various formulations and may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, external preparations such as syrups and aerosols, and sterilized suppository solutions according to a conventional method . In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used, and the preparations for non-oral administration include sterilized aqueous solutions, Emulsions, freeze-dried preparations, suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
상기 항산화 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물의 형태, 투여경로 및 기간에 따라 적절하게 선택될 수 있다. 그러나 바람직한 항산화 효과를 위해서, 본 발명의 추출물 또는 화합물은 1일 0.01 내지 500mg/kg으로, 바람직하게는 0.1 내지 200mg/kg의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 또한 그 화합물의 투여량은 투여 경로, 질병의 정도, 성별, 체중, 나이 등에 따라 증감될 수 있다.The desired dosage of the antioxidant composition may be appropriately selected depending on the condition and body weight of the patient, the degree of disease, the form of the drug, the route of administration and the period of time. However, for the desired antioxidative effect, the extract or the compound of the present invention may be administered in an amount of 0.01 to 500 mg / kg, preferably 0.1 to 200 mg / kg per day, once or several times per day. The dose of the compound may also be increased or decreased depending on the route of administration, degree of disease, sex, weight, age, and the like.
본 발명의 다른 일 실시예에 따른 항염증 약학조성물은 좀딱취(Ainsliaea apiculata) 추출물을 함유한다. 상기 항염증 약학조성물에 대한 설명 중에서 상기 항산화 약학조성물과 중복되는 설명은 기재를 생략한다.The anti-inflammatory pharmaceutical composition according to another embodiment of the present invention contains Ainsliaea apiculata extract. Among the descriptions of the antiinflammatory pharmaceutical composition, the description overlapping with the antioxidant pharmaceutical composition is omitted.
상기 좀딱취 추출물은 염증매개인자인 iNOS의 발현을 억제하고 이 효소에 의해 생성되는 NO의 발현을 억제하여 염증 관련 질병의 예방과 치료에 유용한 성분을 함유하여 항산화 활성의 약학적 조성물로 활용될 수 있으며, 좋게는 염증성 질환의 예방 또는 치료용 약학적 조성물로 활용될 수 있고, 외부 세균으로부터의 감염에 의한 염증의 예방 또는 치료용 약학적 조성물을 제공한다.The extract of Corynebacterium sp. Can inhibit the expression of iNOS as an inflammatory mediator and inhibit the expression of NO produced by the enzyme. Thus, the extract can be used as a pharmaceutical composition for antioxidant activity containing a compound useful for the prevention and treatment of inflammation-related diseases Which can be preferably used as a pharmaceutical composition for the prevention or treatment of inflammatory diseases and provides a pharmaceutical composition for preventing or treating inflammation caused by infection from external bacteria.
본 발명의 또 다른 일 실시예에 따른 식품조성물은, 좀딱취(Ainsliaea apiculata) 추출물을 함유하여 항염증 및 우수한 항산화 기능을 가지며, 건강기능식품, 영양보조제, 건강식품, 또는 식품첨가물의 형태로 식품조성물로 활용될 수 있다.The food composition according to another embodiment of the present invention contains an extract of Ainsliaea apiculata and has an anti-inflammatory and excellent antioxidative function and can be used as a health food, a nutritional supplement, a health food, Can be utilized as a composition.
상기 유형의 식품 조성물은 통상적인 방법에 따라 다양한 형태로 제조할 수 있다. 예를 들면, 건강식품으로는 상기 좀딱취 추출물 자체를 차, 쥬스 및 드링크의 형태로 제조하여 음용할 수 있도록 액상화, 과립화, 캡슐화 및 분말화하여 섭취할 수 있다. 또한, 상기 좀딱취 추출물과 항염 효과가 있다고 알려진 공지의 활성 성분과 함께 혼합하여 조성물의 형태로 제조할 수 있다. 또한, 기능성 식품으로는 이에 한정되지 않지만 음료(알콜성 음료 포함), 과실과 그의 가공식품(예: 과일통조림, 병조림, 잼, 마아말레이드 등), 어류, 육류 및 이의 가공식품(예: 햄, 소시지 콘비이프 등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게이트, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예: 버터, 치이즈 등), 식용식물 유지, 마아가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 상기 좀딱취 추출물을 첨가하여 제조할 수 있다. 상기 식품조성물 중 상기 좀딱취 추출물의 바람직한 함유량으로는 이에 한정되지 않지만 바람직하게는 최종적으로 제조된 식품 중 0.01 내지 50 중량%이다.Food compositions of this type can be prepared in a variety of forms according to conventional methods. For example, the health food may be prepared by liquefying, granulating, encapsulating, and pulverizing the above-mentioned Corynebacterium extract in the form of tea, juice, and drink so that it can be consumed. In addition, the extract may be mixed with a known scent extract and a known active ingredient known to have anti-inflammatory effects to prepare a composition. Functional foods also include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods such as canned fruits, jars, jam, maare marlade, fish, meat and processed foods (Eg butter, cheeses, etc.), edible vegetable oils (eg, sourdoughs, etc.), breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, , Margarine, vegetable protein, retort food, frozen food, various kinds of seasonings (for example, soybean paste, soy sauce, sauce, etc.). The preferable content of the above-mentioned Corynebacterium sp. Extract in the above food composition is not particularly limited, but is preferably 0.01 to 50% by weight in the finally prepared food.
본 발명의 항산화 조성물, 항염증 조성물 및 식품 조성물은 좀딱취(Ainsliaea apiculata) 추출물을 함유하여, 항산화 활성이 우수하고 염증인자 발현 억제 활성을 가지는 약학조성물 또는 기능성 식품 조성물로 유용하게 활용될 수 있다.The antioxidative composition, antiinflammatory composition and food composition of the present invention contain an extract of Ainsliaea apiculata and can be effectively utilized as a pharmaceutical composition or a functional food composition having an antioxidative activity and an inhibitory effect on the expression of an inflammatory factor.
도 1은 본 발명의 실시예 1에서 제조한 좀딱취 추출물로 처리한 샘플들로부터 생성된 NO의 양을 평가한 결과이다.
도 2은 본 발명의 실시예 1에서 제조한 좀딱취 추출물의 항산화 활성을 이 DPPH 자유 라디칼 소거 활성 분석을 이용하여 평가한 결과이다.FIG. 1 shows the results of evaluation of the amount of NO produced from the samples treated with the scarlet extract prepared in Example 1 of the present invention.
FIG. 2 shows the results of evaluating the antioxidant activity of the extract of Corynebacterium sativus, which is prepared in Example 1 of the present invention, using this DPPH free radical scavenging activity assay.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 첨부한 도면을 참고로 하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.
Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
실시예 1: 좀딱취 추출물의 제조Example 1: Preparation of Chopped Extracts
국내에서 자생하는 좀딱취(Ainsliaea apiculata)의 전초를 채취하여 음지에서 14일 동안 자연 건조한 후 20 매쉬 이하의 크기로 파쇄하여 얻은 좀딱취의 건조분말을 실험에 사용하였다.The outcrops of Ainsliaea apiculata , which is native to Korea, were sampled and dried for 14 days in the shade and then crushed to a size of 20 mesh or less.
좀딱취 건조분말 100g을 에탄올 1L를 넣고, 25℃에서 7일간 동안 냉침하고, 이를 3회 반복하여 추출한 후 여지(와트만사, 미국)로 감압 여과하여 여과추출물을 얻었다. 상기 여과 추출물은 진공회전 농축기를 이용하여 40 ℃에서 에탄올을 제거하여 좀딱취 추출물 잔사를 12 내지 20g을 수득하였다. 이 중 10mg을 취하여 이하 항염증과 항산화 활성검색을 위한 시료로 사용하였다.
1 liter of ethanol was added to 100 g of the dried beaten egg powder, and the mixture was cooled at 25 ° C for 7 days. The mixture was extracted three times and filtered to obtain a filtered extract by filtration under reduced pressure (Wattmann, USA). The filtrate was subjected to removal of ethanol at 40 ° C using a vacuum rotary condenser to obtain 12-20 g of a slightly scooped extract residue. 10 mg of the sample was used as a sample for the detection of anti-inflammatory and antioxidant activity.
실시예 2: 좀딱취 추출물의 항염증 활성Example 2: Anti-inflammatory activity
좀딱취 추출물의 항염증 효능을 NO의 양 측정 및 iNOS(inducible nitric oxide synthase) 분석을 이용하여 확인하였다.The antiinflammatory effect of extracts of Horseradish was confirmed by measuring the amount of NO and using iNOS (inducible nitric oxide synthase) assay.
RAW 264.7 세포를 DMEM 배지를 이용하여 24 웰 플레이트에 10x104 셀/웰로 접종하고, 12시간 동안 배양 후, 각각 실시예 1에서 제조한 좀딱취 추출물(AD) 20, 4, 또는 0.8 ug/ml과 LPS(1μg/ml)를 동시에 함유한 새로운 배지에 처리 처리하여 24시간 배양하였다. 이렇게 배양된 샘플들로부터 세포배양액 중에 존재하는 NO2-의 양을 그리스 시약(Griess reagent)을 이용하여 측정해 생성된 NO의 양과 iNOS 활성도를 측정하였다. 구체적으로, 위에서 배양된 샘플들의 세포배양 상등액 500μl와 그리스 시약(2.5% 술파닐아미드, 10% 인산에 용해된 0.25% 나프틸에틸렌디아민) 50μl를 혼합하여 24 웰 플레이트에서 10분 동안 반응시킨 후 ELISA 리더를 이용하여 540nm에서 흡광도를 측정하였고, 표준 농도 곡선은 DMSO를 연속 희석한 결과를 이용하였으며, 생성된 NO의 양과 iNOS 활성도를 평가하여 그 결과를 도 1과 표 1에 나타냈다. 또한, 비교예1 및 2로 음성대조군(Negative control)과 과 아스피린을 사용한 양성대조군(Positive control)으로 항염증 활성을 비교하였으며, 사용한 아스피린은 약 3.2 μg/mL 농도에서 iNOS 활성을 50% 억제하였고, 100 μg/mL에서는 거의 효과적으로 억제하는 것으로 확인되었다.RAW 264.7 cells were inoculated into a 24-well plate at a density of 10 × 10 4 cells / well using DMEM medium and cultured for 12 hours. The RAW 264.7 cells were inoculated with 20 μl of scarlet extract (AD) 20, 4, or 0.8 μg / ml LPS (1 [mu] g / ml) at the same time, and cultured for 24 hours. From the cultured samples, the amount of NO 2 - present in the cell culture was measured using a Griess reagent, and the amount of NO produced and iNOS activity were measured. Specifically, 500 μl of the cell culture supernatant of the above cultured samples and 50 μl of a grease reagent (2.5% sulfanilamide, 0.25% naphthylethylenediamine dissolved in 10% phosphoric acid) were mixed and reacted on a 24-well plate for 10 minutes, The absorbance at 540 nm was measured using a reader. The standard concentration curve was obtained by serial dilution of DMSO, and the amount of produced NO and the activity of iNOS were evaluated. The results are shown in FIG. 1 and Table 1. In addition, the antiinflammatory activity was compared between the negative control and the positive control using aspirin in Comparative Examples 1 and 2. The aspirin used inhibited iNOS activity by 50% at a concentration of about 3.2 μg / mL , And 100 μg / mL, respectively.
(Aspirin)Positive control group
(Aspirin)
(Negative control)Negative control group
(Negative control)
상기 도 1을 참조하면, 좀딱취 추출물은 LPS로 유도된 RAW 264.7 c세포에서 효과적으로 NO의 생성을 감소시킨다는 점을 확인할 수 있었으며, 감소의 정도가 농도 의존적이라는 점도 확인할 수 있었다. NO는 산화질소 합성효소(NOS)에 의해 L- 아르지닌으로부터 합성된다. 병리적인 조건 하에서 증가된 NO는 염증발생을 촉진하게 되는데, 다른 염증 매개체와 함께 상승효과를 나타내는 iNOS에 의해 NO가 합성된다. 또한, iNOS는 염증성 사이토카인과 박테리아성 엔도톡신(endotoxin)에의 노출에 의하여 강하게 자극된다. 따라서, iNOS에 의한 NO생성을 감소시킬 수 있는 물질은 항염증제로 활용될 수 있다. Referring to FIG. 1, it was confirmed that the sacculifera extract effectively reduced NO production in RAW 264.7 c cells induced by LPS, and the degree of reduction was dose-dependent. NO is synthesized from L-arginine by nitric oxide synthase (NOS). Under pathologic conditions, increased NO promotes the development of inflammation, which is synthesized by iNOS, a synergistic agent with other inflammatory mediators. In addition, iNOS is strongly stimulated by exposure to inflammatory cytokines and bacterial endotoxins. Therefore, a substance capable of reducing NO production by iNOS can be utilized as an anti-inflammatory agent.
또, 상기 표 1을 참조하면, 좀딱취 추출물은 LPS로 유도된 RAW 264.7 세포에서 iNOS에 대한 억제효과를 나타내고, 이는 좀딱취 추출물과의 관계에서 농도의존적이라는 점도 확인할 수 있었다. 염증상태에서 활성화된 iNOS에 의해 생성된 NO는 병리적인 혈관확장, 세포독성, 조직손상 등과 같은 생체에 유해한 작용을 나타낸다. RAW 264.7에 LPS를 처리하여 생성되는 NO와 염증성사이토카인(proinflammatory cytokine)에 대한 좀딱취 추출물의 효과를 살펴본 결과 강한 억제효과를 보였다. 상기 좀딱취 추출물은 LPS로 유도된 NOS 생성량을 농도 의존적으로 감소시키는 결과를 보여주고 있으며, 좀딱취 추출물은 LPS로 유도된 RAW 264.7 세포에서 iNOS 단백질 발현에 강한 억제효과를 가진다는 점을 확인할 수 있다.
In addition, referring to Table 1 above, it was also confirmed that the safflower extract showed an inhibitory effect on iNOS in RAW 264.7 cells induced by LPS, which was concentration-dependent in relation to the safflower extract. NO produced by activated iNOS in inflammatory conditions has deleterious effects on the organism such as pathological vasodilation, cytotoxicity, and tissue damage. RAW 264.7 showed a strong inhibitory effect on the effect of LPS on NO and proinflammatory cytokine. The extracts showed a concentration-dependent reduction of LPS-induced NOS production and that the scarlet extract had a strong inhibitory effect on iNOS protein expression in RAW 264.7 cells induced by LPS .
실시예 3: 좀딱취 추출물의 항산화 활성 평가Example 3 Evaluation of antioxidative activity of extracts
상기 실시예 1에서 제조한 좀딱취 추출물의 항산화 활성을 DPPH 자유라디칼-소거 활성 시험(free Radical-scavenging activity test)을 이용하여 측정하였다. 96-웰 마이크로플레이트의 각 웰에 TBHQ(양성 대조군), 메탄올(음성대조군), 좀딱취 추출물 시료 메탄올 용액(2000, 1000, 200, 125 μg/ml 농도) 20μl를 주입하고, 0.2mM의 DPPH(Sigma chemical Co. USA) 메탄올 용액 180μl을 첨가하여 반응 시켰다. 이 플레이트를 호일로 감싸 빛을 차단하고 상온에서 20분간 반응 시켜 517nm에서 흡광도를 측정하였고, 그 결과는 도 2에 나타내었다.The antioxidant activity of the scarlet extract prepared in Example 1 was measured using a free Radical-scavenging activity test (DPPH). Twenty microliters of TBHQ (positive control), methanol (negative control), and methanol extract of chopped extract (2000, 1000, 200, and 125 μg / ml) were injected into each well of a 96-well microplate and incubated with 0.2 mM DPPH Sigma chemical Co. USA) methanol solution was added to the reaction mixture. The plate was wrapped with a foil to block the light, reacted at room temperature for 20 minutes, and the absorbance at 517 nm was measured. The results are shown in FIG.
상기 도 2를 참조하면 좀딱취 추출물은 DPPH 자유 라디칼을 농도 의존적으로 소거시킨다는 점을 확인할 수 있었으며, 상당히 우수한 항산화 활성을 나타내서 기존의 항산화 기능을 하는 퀴논 동등 이상의 우수한 항산화 작용을 갖는 것을 확인할 수 있었다.
Referring to FIG. 2, it was confirmed that the scarlet extract extracts scavenged DPPH free radicals in a concentration-dependent manner, and exhibited a remarkably superior antioxidative activity, indicating that the extract had an excellent antioxidative activity equivalent to that of quinone equivalent to that of the conventional antioxidative function.
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, Of the right.
Claims (5)
상기 좀딱취 추출물은 탄소수 1 내지 5의 알코올, 헥산, 클로로포름, 주정, 물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나로 냉침법을 이용해 추출한 것인, 항산화 식품 조성물.The method of claim 1, wherein
Wherein the extract is at least one selected from the group consisting of alcohols having 1 to 5 carbon atoms, hexane, chloroform, alcohol, water, and mixtures thereof.
상기 좀딱취 추출물은 좀딱취의 건조분말에 건조중량의 3 내지 20배 중량의 용매를 가하고 20 내지 120 ℃의 추출 온도에서 30분 내지 10일 동안 추출하는 방법으로 1 내지 5회 추출하여 얻어진 추출액 또는 상기 추출액으로부터 용매를 제거한 분말인, 항산화 식품 조성물.The method of claim 1, wherein
The extract is obtained by extracting 1 to 5 times by adding a solvent having a dry weight of 3 to 20 times by weight to a dry powder of bean curd and extracting it at an extraction temperature of 20 to 120 ° C for 30 minutes to 10 days, Wherein the solvent is removed from the extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150019387A KR101687774B1 (en) | 2015-02-09 | 2015-02-09 | COMPOSITION COMPRISING EXTRACT OF Ainsliaea apiculata HAVING ANTI-OXIDANT AND ANTI-INFLAMMATORY ACTIVITY |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150019387A KR101687774B1 (en) | 2015-02-09 | 2015-02-09 | COMPOSITION COMPRISING EXTRACT OF Ainsliaea apiculata HAVING ANTI-OXIDANT AND ANTI-INFLAMMATORY ACTIVITY |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160098570A KR20160098570A (en) | 2016-08-19 |
KR101687774B1 true KR101687774B1 (en) | 2016-12-20 |
Family
ID=56874693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150019387A KR101687774B1 (en) | 2015-02-09 | 2015-02-09 | COMPOSITION COMPRISING EXTRACT OF Ainsliaea apiculata HAVING ANTI-OXIDANT AND ANTI-INFLAMMATORY ACTIVITY |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101687774B1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100720A (en) | 2011-02-15 | 2011-06-22 | 江西本草天工科技有限责任公司 | Ainsliaea fragrans champ caffeoylquinic acid extracts and preparation and application thereof |
JP2014062058A (en) | 2012-09-20 | 2014-04-10 | Kao Corp | Antimicrobial agent and skin external preparation |
CN103933094A (en) | 2014-03-05 | 2014-07-23 | 河南大学 | Ainsliaea fragrans champ extract, extraction method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101335658B1 (en) * | 2011-08-08 | 2013-12-03 | 건국대학교 산학협력단 | Meat products containing extract and method for preparing the same |
-
2015
- 2015-02-09 KR KR1020150019387A patent/KR101687774B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100720A (en) | 2011-02-15 | 2011-06-22 | 江西本草天工科技有限责任公司 | Ainsliaea fragrans champ caffeoylquinic acid extracts and preparation and application thereof |
JP2014062058A (en) | 2012-09-20 | 2014-04-10 | Kao Corp | Antimicrobial agent and skin external preparation |
CN103933094A (en) | 2014-03-05 | 2014-07-23 | 河南大学 | Ainsliaea fragrans champ extract, extraction method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20160098570A (en) | 2016-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kreft | Buckwheat phenolic metabolites in health and disease | |
KR20170066585A (en) | Synergistic composition for osteoarthritis | |
KR20190057225A (en) | A composition having anti-oxidation or anti-inflammation comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
KR20160098571A (en) | COMPOSITION COMPRISING EXTRACT OF Carex scabrifolia Steud HAVING ANTI-INFLAMMATORY AND ANTI-OXIDANT ACTIVITY | |
KR101687770B1 (en) | COMPOSITION COMPRISING EXTRACT OF Eriocaulon decemflorum HAVING ANTI-INFLAMMATORY AND ANTI-OXIDANT ACTIVITY | |
KR20180082352A (en) | Composition for Inhibiting Proliferation of Helicobacter Pylori Comprising Complex Plant Extracts and Uses Thereof | |
KR102086854B1 (en) | Anti-oxidant or anti-inflammatory cosmetic compositions containing the plants extract of Cyperaceae | |
JP2019034920A (en) | PDE5 activity inhibitor | |
KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
KR101879685B1 (en) | Composition for anti-inflammation with nipa fruticans wurmb | |
KR101935689B1 (en) | Composition comprising mixture extract of jujube, licorice and platycodon for enhancing immune response | |
KR20160141463A (en) | Anti-oxidation and anti-inflammatory composition comprising the extract of aralia continentalis | |
KR101466308B1 (en) | Composition containing Anemarrhena asphodeloides Bunge extracts, fractions thereof or compounds isolated therefrom for prevention or treatment of colitis | |
KR101687774B1 (en) | COMPOSITION COMPRISING EXTRACT OF Ainsliaea apiculata HAVING ANTI-OXIDANT AND ANTI-INFLAMMATORY ACTIVITY | |
KR101790657B1 (en) | Extraction of polysaccharides from pine nut cake and composition comprising pine nut extract for enhancement of immunity | |
KR101831438B1 (en) | Composition comprising uldavioside A compound for preventing or treating of inflammatory disease | |
KR101503352B1 (en) | A composition for skin protection including skin aging, anti-inflammatory comprising the extracts of Lactarius hatsudake as an active ingredients | |
KR101747696B1 (en) | A composition comprising compounds isolated from Echinochloa utilis for preventing or treating inflammatory disease | |
JP2005053862A (en) | Prophylactic/therapeutic agent for inflammatory disease | |
KR20160098567A (en) | Composition comprising extract of rhododendron micranthum having anti-oxidant and anti-inflammatory activity | |
KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
KR101845704B1 (en) | Composition comprising kynurenic acid for relieving hangover | |
KR20150085215A (en) | Composition comprising black garlic and Gastrodia elata extract with antioxidant activity and method of making the same | |
KR102291823B1 (en) | Composition for anti-oxidant and anti-inflammation comprising bellflower sprout extract | |
KR20160098568A (en) | COMPOSITION COMPRISING EXTRACT OF Quamoclit angulata HAVING ANTI-INFLAMMATORY ACTIVITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |